TrialJournal for immunotherapy of cancer2022

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.

N Nora Bennani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.